

Synairgen plc
(‘Synairgen’ or the ‘Company’)

Southampton, UK – 30 January 2012: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company with a particular focus on viral defence of the lungs, will announce a preliminary statement of results for the six months ended 31 December 2011 on Wednesday 1 February 2012.

The Company has brought forward its financial year-end from 30 June to 31 December for administrative reasons to expedite the production of its annual report and accounts. As a result the audited financial statements cover the six months ended 31 December 2011 with comparative financial information being given for the year ended 30 June 2011.

-Ends-

For further information, please contact:

Synairgen plc

Richard Marsden, Chief Executive Officer
John Ward, Finance Director

Tel: + 44 (0) 23 8051 2800

FinnCap

Geoff Nash, Christopher Raggett (Corporate Finance)
Stephen Norcross, Simon Starr (Corporate Broking)

Tel: + 44 (0) 20 7220 0500

Newgate Threadneedle

Graham Herring
Josh Royston

Tel: + 44 (0) 20 7653 9850